RU2692479C2 - (5,6-дигидро)пиримидо[4,5-е]индолизины - Google Patents

(5,6-дигидро)пиримидо[4,5-е]индолизины Download PDF

Info

Publication number
RU2692479C2
RU2692479C2 RU2016141405A RU2016141405A RU2692479C2 RU 2692479 C2 RU2692479 C2 RU 2692479C2 RU 2016141405 A RU2016141405 A RU 2016141405A RU 2016141405 A RU2016141405 A RU 2016141405A RU 2692479 C2 RU2692479 C2 RU 2692479C2
Authority
RU
Russia
Prior art keywords
carboxamide
dihydropyrimido
indolizine
anilino
methoxy
Prior art date
Application number
RU2016141405A
Other languages
English (en)
Russian (ru)
Other versions
RU2016141405A (ru
RU2016141405A3 (enExample
Inventor
Ман Адрианус Петрус Антониус де
Рогир Христиан БЁЙСМАН
Ян Герард СТЕРРЕНБУРГ
Йост Корнелис Маринус ЭЙТДЕХАГ
ВИТ Юри Йоханнес Петрус ДЕ
Гёйдо Енни Рюдолф ЗАМАН
Original Assignee
Недерлэндс Транслэшинал Рисерч Сентер Б.В.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Недерлэндс Транслэшинал Рисерч Сентер Б.В. filed Critical Недерлэндс Транслэшинал Рисерч Сентер Б.В.
Publication of RU2016141405A publication Critical patent/RU2016141405A/ru
Publication of RU2016141405A3 publication Critical patent/RU2016141405A3/ru
Application granted granted Critical
Publication of RU2692479C2 publication Critical patent/RU2692479C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RU2016141405A 2014-04-07 2015-03-30 (5,6-дигидро)пиримидо[4,5-е]индолизины RU2692479C2 (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP14163734 2014-04-07
EP14163734.8 2014-04-07
EP15153207 2015-01-30
EP15153207.4 2015-01-30
PCT/EP2015/056839 WO2015155042A1 (en) 2014-04-07 2015-03-30 (5,6-dihydro)pyrimido[4,5-e]indolizines

Publications (3)

Publication Number Publication Date
RU2016141405A RU2016141405A (ru) 2018-05-07
RU2016141405A3 RU2016141405A3 (enExample) 2018-10-02
RU2692479C2 true RU2692479C2 (ru) 2019-06-25

Family

ID=52774240

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2016141405A RU2692479C2 (ru) 2014-04-07 2015-03-30 (5,6-дигидро)пиримидо[4,5-е]индолизины

Country Status (16)

Country Link
US (3) US9856258B2 (enExample)
EP (1) EP3129374B1 (enExample)
JP (1) JP6518690B2 (enExample)
KR (1) KR102432420B1 (enExample)
CN (1) CN106132963B (enExample)
AU (1) AU2015243694B2 (enExample)
BR (1) BR112016022342B1 (enExample)
CA (1) CA2944610C (enExample)
DK (1) DK3129374T3 (enExample)
ES (1) ES2716165T3 (enExample)
HU (1) HUE043108T2 (enExample)
MX (1) MX368767B (enExample)
PL (1) PL3129374T3 (enExample)
PT (1) PT3129374T (enExample)
RU (1) RU2692479C2 (enExample)
WO (1) WO2015155042A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2852026C2 (ru) * 2022-03-04 2025-12-02 Силладжен, Инк. Фармацевтические комбинации для применения при лечении неопластических заболеваний

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2944610C (en) * 2014-04-07 2024-01-09 Netherlands Translational Research Center B.V. (5,6-dihydro)pyrimido[4,5-e]indolizines
EP3283642B1 (en) * 2015-04-17 2023-10-11 Netherlands Translational Research Center Holding B.V. Prognostic biomarkers for ttk inhibitor chemotherapy
WO2017141116A1 (en) * 2016-02-19 2017-08-24 Phoenix Molecular Designs Carboxamide derivatives useful as rsk inhibitors
KR102218333B1 (ko) 2016-06-07 2021-02-22 자코바이오 파마슈티칼스 컴퍼니 리미티드 Shp2 억제제로서 유용한 신규한 헤테로환형 유도체
CN106551938B (zh) * 2016-11-26 2017-11-24 广东安诺药业股份有限公司 一种治疗非酒精性脂肪肝的药物及其应用
SG11201908820VA (en) 2017-03-23 2019-10-30 Jacobio Pharmaceuticals Co Ltd Novel heterocyclic derivatives useful as shp2 inhibitors
CN112839935A (zh) 2018-09-26 2021-05-25 北京加科思新药研发有限公司 可用作shp2抑制剂的新型杂环衍生物
US12378245B2 (en) 2019-02-11 2025-08-05 Phoenix Molecular Designs Crystalline forms of an RSK inhibitor
JP2024546977A (ja) * 2021-12-15 2024-12-26 シルラジェン，インコーポレイテッド 新生物疾患の処置方法
MX2024007450A (es) * 2021-12-15 2024-07-04 Sillajen Inc Combinaciones farmaceuticas para utilizarse en el tratamiento de enfermedades neoplasicas.
MX2024007452A (es) * 2021-12-15 2024-07-09 Sillajen Inc Composiciones farmaceuticas que comprenden beta-ciclodextrinas modificadas.
KR20240144991A (ko) * 2022-03-04 2024-10-04 신라젠(주) 신생물성 질환 치료에 사용하기 위한 약제학적 병용물

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA007983B1 (ru) * 2001-09-19 2007-02-27 Авентис Фарма С.А. Индолизины в качестве ингибиторов киназных белков
WO2009156315A1 (en) * 2008-06-26 2009-12-30 Nerviano Medical Sciences S.R.L. Pyrazolo-quinazolines
WO2012101032A1 (en) * 2011-01-26 2012-08-02 Nerviano Medical Sciences S.R.L. Tricyclic pyrrolo derivatives, process for their preparation and their use as kinase inhibitors

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2436524T3 (es) 2003-05-22 2014-01-02 Nerviano Medical Sciences S.R.L. Derivados de pirazolo-quinazolina, procedimiento para su preparación y su uso como inhibidores de cinasas
JP5284973B2 (ja) 2006-11-28 2013-09-11 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ 三環式インドールおよび（４，５−ジヒドロ）インドール
WO2010111406A2 (en) 2009-03-24 2010-09-30 Myriad Pharmaceuticals, Inc. Compounds and therapeutic uses thereof
WO2010125004A1 (en) 2009-04-29 2010-11-04 Nerviano Medical Sciences S.R.L. Cdk inhibitor salts
ES2553114T3 (es) 2009-07-29 2015-12-04 Nerviano Medical Sciences S.R.L. Sales de inhibidor de plk
TW201107329A (en) 2009-07-30 2011-03-01 Oncotherapy Science Inc Fused imidazole derivative having ttk inhibitory action
EP2343297A1 (en) 2009-11-30 2011-07-13 Bayer Schering Pharma AG Triazolopyridines
CA2821829A1 (en) 2010-12-17 2012-06-21 Bayer Intellectual Property Gmbh Imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders
EP3013823B1 (en) 2013-06-24 2017-11-01 Merck Patent GmbH Imidazole compounds as modulators of fshr and uses thereof
CA2944610C (en) * 2014-04-07 2024-01-09 Netherlands Translational Research Center B.V. (5,6-dihydro)pyrimido[4,5-e]indolizines

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA007983B1 (ru) * 2001-09-19 2007-02-27 Авентис Фарма С.А. Индолизины в качестве ингибиторов киназных белков
WO2009156315A1 (en) * 2008-06-26 2009-12-30 Nerviano Medical Sciences S.R.L. Pyrazolo-quinazolines
WO2012101032A1 (en) * 2011-01-26 2012-08-02 Nerviano Medical Sciences S.R.L. Tricyclic pyrrolo derivatives, process for their preparation and their use as kinase inhibitors

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2852026C2 (ru) * 2022-03-04 2025-12-02 Силладжен, Инк. Фармацевтические комбинации для применения при лечении неопластических заболеваний

Also Published As

Publication number Publication date
US9856258B2 (en) 2018-01-02
RU2016141405A (ru) 2018-05-07
BR112016022342A2 (pt) 2017-08-15
USRE48974E1 (en) 2022-03-15
CA2944610A1 (en) 2015-10-15
CN106132963B (zh) 2019-08-06
MX368767B (es) 2019-10-15
EP3129374A1 (en) 2017-02-15
PL3129374T3 (pl) 2019-07-31
DK3129374T3 (en) 2019-04-08
KR102432420B1 (ko) 2022-08-17
US20170096432A1 (en) 2017-04-06
WO2015155042A1 (en) 2015-10-15
PT3129374T (pt) 2019-03-25
EP3129374B1 (en) 2018-12-19
AU2015243694B2 (en) 2019-01-17
USRE50082E1 (en) 2024-08-20
AU2015243694A1 (en) 2016-11-03
CA2944610C (en) 2024-01-09
JP6518690B2 (ja) 2019-05-22
BR112016022342A8 (pt) 2021-07-20
MX2016012997A (es) 2016-12-07
RU2016141405A3 (enExample) 2018-10-02
JP2017510595A (ja) 2017-04-13
CN106132963A (zh) 2016-11-16
KR20170013866A (ko) 2017-02-07
BR112016022342B1 (pt) 2022-10-04
HUE043108T2 (hu) 2019-07-29
ES2716165T3 (es) 2019-06-10

Similar Documents

Publication Publication Date Title
USRE48974E1 (en) (5,6-dihydro)pyrimido[4,5-E]indolizines
CN114269735B (zh) 二氢或四氢喹唑啉类化合物及其中间体、制备方法和应用
CN103889962B (zh) 作为受体酪氨酸激酶btk抑制剂的取代的n‑(3‑(嘧啶‑4‑基)苯基)丙烯酰胺类似物
EP3173412B1 (en) 2,4-disubstituted 7h-pyrrolo[2,3-d]pyrimidine derivative, preparation method and medicinal use thereof
JP2022516469A (ja) ユビキチン特異的プロテアーゼ１を阻害するための組成物
EP3621968A1 (en) Heteroaryl compounds that inhibit g12c mutant ras proteins
KR20130096241A (ko) Ａｌｋ 억제제로서 4-(1ｈ-인돌-3-일)-피리미딘
KR20170101908A (ko) 피리미딘 또는 피리딘계 화합물, 이의 제조방법 및 약학적 용도
AU2013344049A1 (en) ALK kinase inhibitors
ES2878078T3 (es) Inhibidores de GSK-3
EP3169687B1 (en) FUSED QUINOLINE COMPUNDS AS PI3K, mTOR INHIBITORS
WO2023110970A1 (en) Macrocyclic btk inhibitors
CN104837844A (zh) 作为酪蛋白激酶1 d/e抑制剂的吡唑取代的咪唑并哌嗪
CN112313207A (zh) 一种氰基取代吡啶及氰基取代嘧啶类化合物、制备方法及其应用
ES2905985T3 (es) Compuesto de oxazino-quinazolina y de tipo oxazino-quinazolina, método de preparación y usos de los mismos
AU2016293841B2 (en) Fused quinoline compunds as pi3k/mTor inhibitors
ES2896938T3 (es) Inhibidores de GSK-3
CN103570731A (zh) 嘧啶并三环或嘧啶并四环类化合物及其药用组合物和应用
HK1231072A1 (en) (5,6-dihydro)pyrimido[4,5-e]indolizines
HK1231072B (en) (5,6-dihydro)pyrimido[4,5-e]indolizines
CN116478100A (zh) 喹唑啉类衍生物及其制备方法和用途
EA047866B1 (ru) Ингибиторы мутантных белков kras
HK40042713A (en) Oxazino-quinazoline and oxazino-quinazoline type compound, preparation method therefor, and uses thereof
HK40042713B (en) Oxazino-quinazoline and oxazino-quinazoline type compound, preparation method therefor, and uses thereof